Open AccessComments on validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease
Author(s) -
JianGuo Hong,
Lun-Jie Yan,
Xian Li,
Shengyu Yao,
Su Peng,
Haichao Li,
Zi-Niu Ding,
Dongxu Wang,
ZhaoRu Dong,
Tao Li
Publication year - 2022
Publication title -
world journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v28.i6.689
Subject(s) - nonalcoholic fatty liver disease , fatty liver , medicine , alanine aminotransferase , gastroenterology , fibrosis , hepatic fibrosis , body mass index , disease , diabetes mellitus , liver fibrosis , severity of illness , endocrinology
To evaluate and predict liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), several non-invasive scoring systems were built and widely used in the progress of diagnosis and treatment, which showed great diagnostic efficiency, such as aspartate aminotransferase to platelet ratio index, fibrosis-4 index, body mass index, aspartate aminotransferase to alanine aminotransferase ratio, diabetes score and NAFLD fibrosis score. Since the new concept of metabolic associated fatty liver disease (MAFLD) was proposed, the clinical application value of the non-invasive scoring systems mentioned above has not been assessed in MAFLD. The evaluation of the diagnostic performance of these non-invasive scoring systems will provide references for clinicians in the diagnosis of MAFLD.